EUCTR2016-003883-38-NL进行中（未招募）1 期
A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients with Septic Shock and Elevated Adrenomedullin - AdrenOSS-2
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Adrenomed AG
- 入组人数
- 301
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent by patient or legally designated representative
- •(according to country – specific regulations)
- •2. Male and female patient, age = 18 years
- •3. Body weight 50 kg – 120 kg
- •4. Bio-ADM concentration > 70 pg/ml
- •5. Patient with early septic shock (start of vasopressor therapy
- •< 12 hours)
- •6. Women of childbearing potential must have a negative pregnancy serum or urine pregnancy test before randomization
- •7. Highly effective method of contraception must be maintained for 6 months after study start by women of childbearing potential and sexually active men.
- •8. No care limitation
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 150
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 150
排除标准
- •1. Moribund
- •2. Pre-existing unstable condition (e.g. a recent cerebral hemorrhage or infarct, a recent acute unstable myocardial infarction (all < 3 months), congestive heart failure – NYHA Class IV)
- •3. Patients that required cardiopulmonary resuscitation in the last 4 weeks prior to evaluation for enrollment
- •4. Severe COPD with chronic oxygen need at home (GOLD IV)
- •5. Any organ or bone marrow transplant within the past 24 weeks
- •6. Uncontrolled serious hemorrhage (= 2 units of blood / platelets in the previous 24 hrs.). Patients may be considered for enrollment if bleeding has stopped and patient is otherwise qualified
- •7. Uncontrolled hematological / oncological malignancies
- •8. Absolute neutropenia < 500 per µL
- •9. Severe chronic liver disease (Child-Pugh C)
- •10. Systemic fungal infection or active tuberculosis
- •11. Neuromuscular disorders that impact breathing / spontaneous ventilation
- •12. Burns > 30% of body surface
- •13. Plasmapheresis
- •14. Breastfeeding women
- •15. Participation in a clinical trial involving another investigational drug within 4 weeks prior to inclusion
- •16. Unwilling or unable to be fully evaluated for all follow-up visits
研究者
相似试验
已完成
不适用
A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Oral Dose Study to Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of JNJ-26070109 In Healthy SubjectsNL-OMON30846Janssen-Cilag90
进行中（未招募）
1 期
Trial comparing Standard Treatment in the ICU with ADRECIZUMAB Treatment in patients with septic shock and elevated AdrenomedulliMedDRA version: 20.0 Level: PT Classification code 10040070 Term: Septic shock System Organ Class: 10021881 - Infections and infestationsSeptic ShockEUCTR2016-003883-38-BEAdrenomed AG300
进行中（未招募）
1 期
A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose, Safety Study of MYO-029 Administered to Adult Patients with Becker, Facioscapulohumeral and Limb-Girdle Muscular Dystrophy.Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy.EUCTR2004-000622-67-GBWyeth Research Division of Wyeth Pharmaceuticals Inc.136
进行中（未招募）
2 期
Medical expulsive effect using TadalafilreterolithiasisJPRN-jRCT2031190051Arai Seiji50
进行中（未招募）
1 期
A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production, Administered Subcutaneously over 12 Weeks in Patients with Chronic Heart Failure with Reduced Ejection FractioChronic Heart Failure with Reduced Ejection FractionMedDRA version: 20.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849EUCTR2020-005878-10-PLIonis Pharmaceuticals72